| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 43 | 2024 | 1866 | 4.350 |
Why?
|
| Hypercalcemia | 8 | 2023 | 137 | 3.110 |
Why?
|
| Carcinoma, Neuroendocrine | 23 | 2024 | 716 | 2.940 |
Why?
|
| Bone Density Conservation Agents | 9 | 2023 | 198 | 2.840 |
Why?
|
| Proto-Oncogene Proteins c-ret | 20 | 2024 | 370 | 2.120 |
Why?
|
| Diphosphonates | 9 | 2023 | 262 | 1.190 |
Why?
|
| Carcinoma, Medullary | 6 | 2017 | 248 | 1.180 |
Why?
|
| Denosumab | 5 | 2021 | 68 | 1.140 |
Why?
|
| RANK Ligand | 3 | 2015 | 119 | 1.060 |
Why?
|
| Pyridines | 11 | 2024 | 1244 | 1.060 |
Why?
|
| Thyroid Nodule | 2 | 2021 | 92 | 0.930 |
Why?
|
| Multiple Endocrine Neoplasia | 2 | 2020 | 57 | 0.830 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2021 | 82 | 0.790 |
Why?
|
| Bone Resorption | 3 | 2014 | 138 | 0.760 |
Why?
|
| Piperidines | 6 | 2024 | 1035 | 0.740 |
Why?
|
| Quinazolines | 5 | 2023 | 923 | 0.730 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2015 | 3251 | 0.720 |
Why?
|
| Thyroid Gland | 2 | 2021 | 355 | 0.710 |
Why?
|
| Bone Neoplasms | 5 | 2021 | 2576 | 0.660 |
Why?
|
| Neoplasms | 13 | 2023 | 15193 | 0.650 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2024 | 4757 | 0.630 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 1283 | 0.580 |
Why?
|
| Pyrazoles | 8 | 2024 | 1471 | 0.540 |
Why?
|
| Thyroidectomy | 8 | 2020 | 486 | 0.540 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 14289 | 0.450 |
Why?
|
| Hypoparathyroidism | 1 | 2011 | 49 | 0.380 |
Why?
|
| Humans | 75 | 2024 | 261506 | 0.360 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2010 | 84 | 0.360 |
Why?
|
| Osteonecrosis | 3 | 2020 | 53 | 0.360 |
Why?
|
| Pyrimidines | 5 | 2024 | 3518 | 0.350 |
Why?
|
| Point Mutation | 1 | 2012 | 769 | 0.340 |
Why?
|
| Anilides | 4 | 2024 | 268 | 0.300 |
Why?
|
| Germ-Line Mutation | 5 | 2017 | 1046 | 0.290 |
Why?
|
| Middle Aged | 35 | 2021 | 86204 | 0.260 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 2 | 2017 | 115 | 0.250 |
Why?
|
| Male | 39 | 2021 | 123000 | 0.250 |
Why?
|
| Pheochromocytoma | 3 | 2018 | 281 | 0.240 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 5159 | 0.240 |
Why?
|
| Carcinoma | 4 | 2019 | 2578 | 0.230 |
Why?
|
| Vitamin D | 3 | 2016 | 261 | 0.230 |
Why?
|
| Female | 38 | 2021 | 141928 | 0.230 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 502 | 0.220 |
Why?
|
| Aged | 28 | 2021 | 70117 | 0.210 |
Why?
|
| Adrenal Gland Neoplasms | 3 | 2018 | 489 | 0.210 |
Why?
|
| Niacinamide | 2 | 2014 | 421 | 0.210 |
Why?
|
| Phenylurea Compounds | 3 | 2014 | 580 | 0.210 |
Why?
|
| Adult | 28 | 2024 | 77950 | 0.210 |
Why?
|
| Hypophysitis | 1 | 2021 | 10 | 0.200 |
Why?
|
| Receptor, trkA | 1 | 2021 | 35 | 0.200 |
Why?
|
| Neck Dissection | 3 | 2017 | 290 | 0.190 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 49 | 0.190 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 194 | 0.190 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2020 | 37 | 0.180 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2019 | 6 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2019 | 53 | 0.170 |
Why?
|
| Hypothyroidism | 1 | 2021 | 204 | 0.170 |
Why?
|
| Young Adult | 12 | 2019 | 21445 | 0.170 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 166 | 0.170 |
Why?
|
| Disease Management | 4 | 2020 | 1052 | 0.170 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2018 | 36 | 0.170 |
Why?
|
| Thyrotoxicosis | 1 | 2018 | 22 | 0.170 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.160 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 5767 | 0.160 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 311 | 0.160 |
Why?
|
| Retrospective Studies | 16 | 2023 | 37905 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 2019 | 185 | 0.150 |
Why?
|
| Mutation | 6 | 2021 | 15179 | 0.150 |
Why?
|
| Drug Eruptions | 1 | 2019 | 256 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 332 | 0.150 |
Why?
|
| Hypophosphatemia | 2 | 2014 | 26 | 0.140 |
Why?
|
| Adrenalectomy | 2 | 2015 | 188 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2021 | 156 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.140 |
Why?
|
| Syndrome | 2 | 2011 | 1351 | 0.140 |
Why?
|
| Melanoma | 3 | 2018 | 5317 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 250 | 0.140 |
Why?
|
| Paraganglioma | 1 | 2018 | 170 | 0.140 |
Why?
|
| Vitamin D Deficiency | 2 | 2014 | 115 | 0.140 |
Why?
|
| Femoral Fractures | 1 | 2016 | 50 | 0.140 |
Why?
|
| Aluminum Silicates | 1 | 2015 | 15 | 0.140 |
Why?
|
| Antidiarrheals | 1 | 2015 | 37 | 0.130 |
Why?
|
| Physician's Role | 1 | 2018 | 238 | 0.130 |
Why?
|
| Carboplatin | 1 | 2018 | 823 | 0.130 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2018 | 135 | 0.130 |
Why?
|
| Patient Selection | 2 | 2020 | 2055 | 0.130 |
Why?
|
| Spinal Fractures | 1 | 2016 | 132 | 0.130 |
Why?
|
| Spinal Cord Compression | 1 | 2016 | 151 | 0.130 |
Why?
|
| Adrenal Glands | 1 | 2015 | 122 | 0.130 |
Why?
|
| Calcium | 2 | 2011 | 1537 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| Therapeutics | 1 | 2014 | 34 | 0.120 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2014 | 28 | 0.120 |
Why?
|
| Esophageal Fistula | 1 | 2014 | 27 | 0.120 |
Why?
|
| Respiratory Tract Fistula | 1 | 2014 | 33 | 0.120 |
Why?
|
| Osteocalcin | 2 | 2012 | 87 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.120 |
Why?
|
| Acromegaly | 1 | 2013 | 27 | 0.120 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2014 | 67 | 0.120 |
Why?
|
| Risk Factors | 9 | 2020 | 17523 | 0.110 |
Why?
|
| Sezary Syndrome | 1 | 2014 | 159 | 0.110 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2015 | 172 | 0.110 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 334 | 0.110 |
Why?
|
| Internationality | 1 | 2014 | 208 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2019 | 2588 | 0.110 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2015 | 223 | 0.110 |
Why?
|
| Octreotide | 1 | 2013 | 118 | 0.110 |
Why?
|
| Neoplasm Metastasis | 6 | 2021 | 5112 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 527 | 0.110 |
Why?
|
| Aged, 80 and over | 10 | 2018 | 29902 | 0.110 |
Why?
|
| Indoles | 2 | 2015 | 1009 | 0.100 |
Why?
|
| Treatment Outcome | 9 | 2015 | 32848 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Iodine Radioisotopes | 2 | 2024 | 371 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1910 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 607 | 0.100 |
Why?
|
| Diarrhea | 1 | 2015 | 686 | 0.100 |
Why?
|
| Prognosis | 7 | 2021 | 21713 | 0.100 |
Why?
|
| Paclitaxel | 1 | 2018 | 1996 | 0.100 |
Why?
|
| Hypocalcemia | 1 | 2011 | 59 | 0.100 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 320 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 876 | 0.100 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2011 | 24 | 0.100 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 2283 | 0.100 |
Why?
|
| Contraindications | 1 | 2011 | 150 | 0.100 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2010 | 53 | 0.100 |
Why?
|
| Jaw Diseases | 1 | 2010 | 21 | 0.100 |
Why?
|
| Disease Progression | 5 | 2023 | 6682 | 0.090 |
Why?
|
| Parathyroidectomy | 1 | 2012 | 203 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 4938 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 15862 | 0.090 |
Why?
|
| Cushing Syndrome | 1 | 2011 | 70 | 0.090 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2014 | 1756 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 661 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1589 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 589 | 0.090 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 33 | 0.090 |
Why?
|
| Breast Neoplasms | 4 | 2013 | 15694 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 2170 | 0.080 |
Why?
|
| Adolescent | 7 | 2019 | 31252 | 0.080 |
Why?
|
| Jaw Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
| Research | 1 | 2011 | 415 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 3719 | 0.080 |
Why?
|
| Bone Diseases | 1 | 2009 | 143 | 0.080 |
Why?
|
| Recurrence | 2 | 2013 | 4758 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4367 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.080 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 11538 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6207 | 0.080 |
Why?
|
| Calcitonin | 2 | 2020 | 186 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.080 |
Why?
|
| Bone Density | 1 | 2010 | 476 | 0.070 |
Why?
|
| Incidence | 2 | 2016 | 5673 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 649 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 622 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2020 | 690 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 1248 | 0.070 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 406 | 0.070 |
Why?
|
| Neoplasm Staging | 5 | 2023 | 13658 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2015 | 1823 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2014 | 2054 | 0.070 |
Why?
|
| Genotype | 2 | 2017 | 4109 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2007 | 291 | 0.060 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 634 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 7789 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 10001 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2019 | 6869 | 0.060 |
Why?
|
| Estrogens | 1 | 2007 | 751 | 0.060 |
Why?
|
| Testosterone | 1 | 2007 | 619 | 0.050 |
Why?
|
| Pedigree | 2 | 2017 | 1890 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 4975 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2019 | 12873 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4654 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2023 | 587 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 14889 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8873 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 543 | 0.050 |
Why?
|
| Carcinoma, Papillary | 2 | 2015 | 584 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 447 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 163 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2014 | 5542 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2001 | 370 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 5539 | 0.040 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2018 | 24 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 38 | 0.040 |
Why?
|
| Osteolysis | 1 | 2018 | 80 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 2231 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2020 | 6100 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 294 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 755 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2403 | 0.040 |
Why?
|
| United States | 2 | 2023 | 15433 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 5377 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 4988 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 9180 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2018 | 380 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 289 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 1290 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 980 | 0.030 |
Why?
|
| Child | 5 | 2016 | 29154 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1239 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2015 | 46 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 9244 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 499 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 752 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 381 | 0.030 |
Why?
|
| Comorbidity | 2 | 2011 | 2352 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 2594 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 833 | 0.030 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2014 | 82 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 6311 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 144 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 1020 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2018 | 710 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12221 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 2314 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1363 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 1863 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 8865 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 135 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 7551 | 0.030 |
Why?
|
| Professional Practice | 1 | 2012 | 82 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 91 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 1084 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 14551 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 829 | 0.030 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2011 | 34 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 827 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 344 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 2011 | 111 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3203 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1742 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2014 | 16273 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 383 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2010 | 142 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 1391 | 0.020 |
Why?
|
| Threonine | 1 | 2010 | 161 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 672 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2018 | 4307 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2001 | 4078 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2014 | 558 | 0.020 |
Why?
|
| Methionine | 1 | 2010 | 159 | 0.020 |
Why?
|
| Alanine | 1 | 2010 | 240 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 665 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2291 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1209 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 576 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 3341 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3230 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3821 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2009 | 23 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4744 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 3890 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 1546 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2803 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4892 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 1152 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 2010 | 2138 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 1392 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2001 | 5270 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 1154 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 2218 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2009 | 411 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2009 | 451 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 3890 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2086 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5687 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1382 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4298 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 2518 | 0.010 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2001 | 30 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 4532 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2001 | 260 | 0.010 |
Why?
|
| Mice | 2 | 2018 | 34495 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 682 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 5047 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5319 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 508 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 5178 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2001 | 626 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2001 | 1082 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 13310 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 1519 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2001 | 619 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2001 | 993 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2001 | 1869 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 2489 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 59536 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 1013 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 12926 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 5395 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 5637 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 4053 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2001 | 11965 | 0.000 |
Why?
|